Summary
We studied the effect of pyridoxal-5•OE-phosphate (PAL-P) 
RESULTS

Experiment 1. Inhibition of glycosylation by PAL-P in vitro (the browning phe nomenon)
After incubation with lysine and glucose for 7 days, a unique pattern appeared in the absorption spectrum, consisting of a broad shoulder at about 330nm which indicated the presence of the browning phenomenon (9) .
The addition of PAL-P to the solution inhibited the occurrence of this phenomenon ( Fig. 1 ). 
Pre-incubation spectra of the same mixture as in (C) .
Experiment 2. Inhibition of protein glycosylation and basement membrane thick ening by PAL-P in vivo 1) Body weight. The body weight increased at the same rate in all groups , with no differences observed between the groups.
2) Serum glucose. The serum glucose concentrations of NSY mice ad ministered PAL-P or physiological saline were much higher than the level in the normal control mice, but there was no significant difference between the two NSY groups (Fig. 2). 3) GHb. The GHb value was higher in both the PAL-P and physiological The serum glucose levels in the PAL -P and physiological saline-treated groups were higher than those in the normal control group. However, no difference was observed between the groups of NSY mice.
saline-treated groups of NSY mice than in the normal control mice. In the NSY mice receiving PAL-P, however, the GHb value decreased slightly after 8 weeks of administration (p<0.1) (Fig. 3) . 4) Fructosamine. The serum fructosamine level was much higher in the physiological saline-treated NSY mice than in the control mice, but in the PAL P-treated NSY mice the level was similar to that in the normal control group. After. 8 weeks of treatment, the difference between the PAL-P and saline groups of NSY mice was significant (p<0.01) (Fig. 4) . S) Pathological features Light microscopy: Periodic acid-Schiff staining showed diffuse glomerulo Fig. 3 . Changes in GHb levels. The GHb levels in both NSY mouse groups were higher than in the normal control group, but in the PAL-P-treated group the mean value fell during the experimental period. Fig. 4 . Changes in serum fructosamine levels.
The serum fructosamine was high in both NSY mouse groups, but in the PAL-P group, serum fructosamine was reduced and no significant difference was seen after 2 months administration. sclerosis, an increase in the mesangial matrix, and thickening of the glomerular basement membrane in the physiological saline-treated group of NSY mice ( Fig .  5(A) ). The PAL-P-treated NSY mice, by contrast, had a similar histological appearance to the normal control mice (Fig. 5(B) ) . Electron microscopy: In the physiological saline-treated NSY mice , an in crease in the amount of mesangial matrix was noted by electron microscopy , and the matrix was seen to be aggregated into nodules. The glomerular basement membrane showed segmental thickening and its overall width was greater than normal. Homogeneous thickening of the lamina densa and the subendothelial accumulation of microfibrillar material were observed. Some podocytes had undergone degeneration and become detached from the underlying glomerular basement membrane (Fig. 6(A) ). In the PAL-P-treated NSY mice , these features were extremely rare compared with the saline-treated mice (Fig. 6(B) ) . The thickness of the glomerular membrane was significantly greater in NSY mice compared to the control mice, but the PAL-P-treated NSY mice had significantly less thickening than saline-treated NSY mice (p<0.01) (Fig. 7) .
DISCUSSION
It has been reported that the injection of glycosylated plasma proteins pro Vol. 37, No. 2, 1991 duces a pseudodiabetic thickening of the renal glomerular basement membrane in mice (10) . The hypothesis that the non-enzymatic glycosylation of albumin might be a model reaction relevant to the pathogenesis of certain complications of chronic diabetes emerged with the demonstration that a variety of other proteins are also subject to glycosylation under physiologic conditions. This concept soon attracted the interest of investigators concerned with the biochemical basis of diabetic sequelae (11, 12) . Mary of the proteins from the tissues typically involved in diabetic complications, such as the glomerular basement membrane, have now been studied (1-6). Although non-enzymatic glycosylation also occurs under normal conditions, the chronic hyperglycemia characteristic of diabetes mellitus appears to be associated with an increase in the glycosylation process and thus with alteration in the function of circulating proteins, such as hemoglobin (13, 14) , albumin (15 , 16) , and low-density lipoprotein (17) (18) (19) . The kidney also appears to be affected by this process, since the increased non-enzymatic glycosylation of glomerular base ment membrane collagen has been reported in both diabetic rats (20) and humans (21) .
The pathological characteristics of the diabetic kidney are generally described as a thickened glomerular basement membrane and the presence of linear deposits of immunoglobulin, fibrin, complement factor C3 (22) , and albumin (23) along the membrane. As the presence of immunoglobulins does not appear to be correlated with an active immunological process (24) , the additional presence of non immunological proteins is suggestive of the secondary binding or trapping of protein by the glomerular basement membrane. Such a phenomenon could be due to an altered chemical composition or "reactivity" of the glomerular basement membrane and/or the proteins themselves. The non-enzymatic glycosylation of the glomerular basement membrane might offer an explanation for these changes occurring in diabetes. Various researchers have sought to find a means to inhibit , or at least reduce, this reaction. Ideally, this would be achieved by the optimization of glycernic control. Since this is still difficult to achieve, however, a second possible approach is pharmaceutical intervention. An important step in this direction has been the observation that aspirin can form an acetyl derivative by reacting with the same free amino acid group of the lysine residue that reacts with glucose (25) . Aspirin can thus inhibit glycosylation by the rapid acetylation of this amino group (26) , which prevents the initial formation of a Schiff's base. The use of aspirin as a glycosylation inhibitor, however, raises the problem of its side-effects, especially at the doses that would be required to obtain a significant level of inhibition . An alternative method to prevent the formation of damaging late glycosylation end products entails the use of aminoguanidine. This nucleophilic hydrazine compound has been shown to prevent the formation of late glycosylation endproducts and thus prevent the development of protein-protein cross links (27) . Its inhibitory mech anism is different from that of aspirin and other acetylating compounds, since the latter inhibit the initial reaction between glucose and the protein amino groups , while aminoguanidine reacts irreversibly with the carbonyl group of the early PYRIDOXAL-5'-PHOSPHATE AND DIABETIC NEPHROPATHY 157 glycosylation product. A third method for reducing the extent of non-enzymatic protein glycosylation is the use of aldehyde, which readily reacts with lysine in solution. We have shown previously that PAL-P could indeed reduce the in vitro non-enzymatic glycosylation of lysine and we also confirmed this finding in the case of the serum protein and hemoglobin of NSY mice in vitro. In this experiment the serum fructosamine level found to be decreased in the PAL-P-treated NSY mice indicated that the in vivo glycosylation of serum protein was also inhibited by PAL-P. When assessing fructosamine levels, numerous factors can interfere with the reaction of the reducing substances. To reduce inaccuracies, blood was collected just before injecting PAL-P into the mice. The half-life of PAL-P is only 1 h and it is readily excreted via the kidneys, so the PAL-P concentration would have been at its lowest level at that time. We also observed a reduction of glomerular basement membrane thickening in the PAL-P-treated NSY mice. High blood aldehyde levels may therefore have prevented a substantial amount of lysine residues from reacting with less accessible amino groups in the circulating and structural proteins. PAL-P is a water-soluble vitamin and excess intake is excreted via the kidneys, so its accumulation to toxic levels is rare.
In conclusion, optimization of glycemic control together with the early phar macological inhibition of non-enzymatic glycosylation might reduce the incidence of diabetic nephropathy, but further studies of this subjects is needed.
